Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy

Journal of Urology

Volumn 170, Issue 5, 2003, Pages 1828-1832

  Zelefsky, Michael J ^a   Marion, Christine ^b   Fuks, Zvi ^b   Leibel, Steven A ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

Age factors; Prostatic neoplasms; Radiotherapy, conformal

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION BEAM; RADIATION DOSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL RATE; TREATMENT FAILURE;

EID: 0141885293     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000093720.46502.24     Document Type: Article

References (20)

1. D'Amico, A. V., Whittington, R., Kaplan, I., Beard, C., Jiroutek, M., Malkowicz, S. B. et al: Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. Int J Radiat Oncol Biol Phys, 37: 1053, 1997
2. Zelefsky, M. J., Wallner, K. E., Ling, C. C., Raben, A., Hollister, T., Wolfe, T. et al: Comparison of the 5-year outcome and morbidity of three dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early stage prostate cancer. J Clin Oncol, 17: 517, 1999
3. Lai, S., Lai, H., Krongrad, A. and Roos, B. A.: Overall and disease-specific survival after radical prostatectomy: geographic uniformity. Urology, 57: 504, 2001
4. Rosser, C. J., Chichakli, R., Levy, L. B., Kuban, D. A., Smith, L. G. and Pisters, L. L.: Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation. J Urol, 168: 536, 2002
5. Pollack, A., Zagars, G. K., Starkschall, G., Antolak, J. A., Lee, J. J., Huang, E. et al: Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys, 53: 1097, 2002
6. Zelefsky, M. J., Fuks, Z., Hunt, M., Lee, H. J., Lombardi, D., Ling, C. C. et al: High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol, 166: 876, 2001
7. Hanks, G. E., Hanlon, A. L., Pinover, W. H., Horwitz, E. M., Price, R. A. and Schultheiss, T.: Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys, 46: 823, 2000
8. Lyons, J. A., Kupelian, P. A., Mohan, D. S., Reddy, C. A. and Klein, E. A.: Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology, 55: 85, 2000
9. Fleming, I. D., Cooper, J. S., Henson, D. E., Hutter, R. V. P., Kennedy, B. J., Murphy, G. P. et al: Prostate. In: American Joint Committee on Cancer. Cancer Staging Manual, 5th ed. Philadelphia: Lippincott-Raven, pp. 181-183, 1997
10. Ling, C. C., Burman, C. M., Chui, C. S., Kutcher, G. J., Leibel, S. A., LoSasso, T. J. et al: Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Phys, 35: 721, 1996
11. Zelefsky, M. J., Fuks, Z., Happersett, L., Lee, H. J., Ling, C. C., Burman, C. M. et al: Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol, 55: 241, 2000
12. Lawton, C. A., Won, M., Pilepich, M. V., Asbell, S. O., Shipley, W. U., Hanks, G. E. et al: Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys, 21: 935, 1991
13. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys, 37: 1035, 1997
14. Kaplan, E. L. and Meier, P.: Nonparametic estimation from incomplete observations. J Am Stat Assoc, 53: 457, 1958
15. Mantel, N.: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep, 50: 163, 1966
16. Cox, D. R.: Regression models and life tables. J R Stat Soc, 34: Series B, 187, 1972
17. Hull, G. W., Rabbani, F., Abbas, F., Wheeler, T. M., Kattan, M. W. and Scardino, P. T.: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol, 167: 528, 2002
18. Amling, C. L., Blute, M. L., Bergstralh, E. J., Seay, T. M., Slezak, J. and Zincke, H.: Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol, 164: 101, 2000
19. Vicini, F. A., Kestin, L. L. and Martinez, A. A.: The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys, 45: 553, 1999
20. Brenner, D. J., Curtis, R. E., Hall, E. J. and Ron, E.: Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer, 88: 398, 2000